基因疗法治艾滋病取得重大进展
http://www.cyol.net 2009-02-18
　　新华网消息 据法新社报道，科学家15日宣布，世界上使用基因疗法治疗艾滋病的最大型试验取得了“重大进展”，证明了这一技术既有益又安全。

　　他们说，这次试验过程的高级阶段的数据表明，寻求用移植基因的方法抑制艾滋病病毒(HIV)是有效的。

　　洛杉矶加利福尼亚大学的罗纳德·光安带领的研究人员招募了74名感染艾滋病病毒的志愿者参加试验，这一试验结果发表在美国《自然-医学》杂志的网站上。

　　这组志愿者中，有一半被植入了血液干细胞，这些干细胞被含有关键基因的受损病毒所感染，而其他人则植入了无害的相似物质。

　　这种基因能为核糖核酸酶编码，该物质是一种微小的分子。一旦细胞感染了艾滋病病毒，核糖核酸酶就会阻碍病毒的复制。

　　干细胞是祖细胞，意味着当这些细胞复制时，其后代将携带同样的基因密码。

　　这些不同寻常的干细胞在核糖核酸酶的作用下不受艾滋病病毒侵害，这样做的目的是确定它们能否在人体的免疫作用下幸存，以及艾滋病病毒在失去繁殖的场所后是否会撤退。

　　这一名为“OZ1”的试验开始48周之后，那些植入基因的志愿者和其他志愿者之间没有数据统计上的区别。

　　但是在100周之后，传来了振奋人心的消息：植入基因者的病毒数量显著减少。而且被艾滋病病毒消灭的免疫细胞

　　CD4细胞的数量增加了。

　　不过新的血液细胞的数量大幅减少。在试验开始4周之后，一项DNA检验发现，有94%的参加试验者出现了这种修改过的细胞，这一数字在48周之后降至12%，在100周后降至7%。

　　所有的参加试验者都没有对这种疗法产生不良反应。

　　研究人员说，这种疗法“是安全的，虽然缓慢但是有效”。“这说明，这种基因疗法有可能治愈艾滋病，并代表该领域取得了重大进展……(它)今后可能被研制成临床用药。”

　　基因疗法作为医学研究的前沿，出现于上个世纪90年代之后。它描绘了这样一个场景：植入细胞的基因能够修复导致疾病的受损基因，或者像在“OZ1”试验中那样，阻碍病原体的发展。

AIDS gene therapy administration made significant progress
http://www.cyol.net 2009-02-18
According to Agence France-Presse, Xinhua News reports, scientists announced on the 15th, the world's use of gene therapy treatment of AIDS has made the biggest test of "significant progress" to prove that this technology is useful and safe.

They said that the trial of the advanced stage of the process data show that the search for ways to use gene transplants inhibit HIV (HIV) are effective.

University of California at Los Angeles Ronald light an led researchers recruited 74 volunteers infected with HIV to participate in the trial, the trial results were published in the United States "Nature - Medicine" magazine's website.

This group of volunteers, half were implanted in the blood stem cells, these stem cells have been damaged gene that contains the key to virus infection, while others have a sound similar to implant material.

The gene coding for RNase, the material is a small molecule. Once the cells infected with the AIDS virus, RNase will hinder virus replication.

Stem cells are progenitor cells, means that when these cells reproduce, their offspring will carry the same genetic code.

Do these unusual cells in the effects of RNase from the AIDS viruses, the purpose of doing so are able to determine their role in the body's immune survivors, as well as the AIDS virus in the loss of breeding grounds for post-whether it will retreat.

This called "OZ1" the beginning of the experiment 48 weeks after implantation of genetically those volunteers and other volunteers have no statistical difference between the data.

However, after 100 weeks, came the exciting news: the viral gene implantation significantly reduced quantity. And was the eradication of HIV immune cells

The number of CD4 cells increased.

But the new quantity of blood cells substantially reduced. During the trial began four weeks after a DNA test found that 94% of those who take part in the pilot that there is such a modified cell, the figure dropped to 48 weeks after 12% after 100 weeks in the reduced to 7%.

All persons to participate in the trial of such therapy have not produced adverse reactions.

The researchers said the therapy "is safe, although a slow but effective." "This shows that such gene therapy may cure AIDS, and on behalf of the field has made significant progress ... ... (which) may be the future development of clinical medicine."

Gene therapy as the forefront of medical research, emerged in the last century after the 90's. It depicts a scene: implanted cells can lead to disease, repair damaged genes, or, as in "OZ1" test, as hindering the development of pathogens.